Iovance Biotherapeutics Balance Sheet
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics financial position
At the end of fiscal 2025, Iovance Biotherapeutics reported total assets of $913.2 million, up 0.3% from a year earlier against total liabilities of $214.6 million. Shareholders' equity stood at $698.6 million, or 76.5% of assets. The company held $163.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.20, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 163.08M | 115.69M | 114.89M | 231.73M | 78.23M | 67.33M | 13.97M | 82.15M | 145.37M | 106.72M |
| Short-Term Investments | 133.90M | 208.09M | 164.98M | 240.11M | 426.18M | 562.11M | 293.11M | 386.37M | 0 | 59.75M |
| Receivables | 82.45M | 69.34M | 151.00K | — | — | — | — | — | — | — |
| Inventory | 51.68M | 51.52M | 10.37M | — | — | — | — | — | — | — |
| Total Current Assets | 442.69M | 457.02M | 307.85M | 479.12M | 507.96M | 636.10M | 316.49M | 475.37M | 149.29M | 169.51M |
| Property, Plant & Equipment | 131.11M | 109.08M | 114.03M | 105.23M | 100.94M | 59.16M | 8.54M | 2.68M | 2.45M | 2.37M |
| Intangible Assets | 279.32M | 282.40M | 229.26M | — | — | — | — | — | — | — |
| Long-Term Investments | — | — | — | — | 91.59M | — | — | — | — | — |
| Total Assets | 913.17M | 910.43M | 780.35M | 663.98M | 777.33M | 768.46M | 344.65M | 480.82M | 155.37M | 171.89M |
| Accounts Payable | 22.16M | 27.51M | 33.12M | 26.60M | 27.38M | 13.51M | 15.57M | 2.74M | 1.23M | 863.00K |
| Total Current Liabilities | 138.36M | 122.34M | 110.31M | 91.48M | 89.20M | 54.87M | 39.08M | 14.40M | 9.60M | 4.97M |
| Long-Term Debt | — | 1.00M | 1.00M | 1.00M | 1.00M | — | — | — | — | — |
| Total Liabilities | 214.59M | 200.02M | 195.74M | 164.34M | 155.67M | 111.96M | 45.68M | 14.63M | 9.89M | 4.97M |
| Shareholders' Equity | 698.58M | 710.40M | 584.61M | 499.64M | 621.66M | 656.50M | 298.97M | 466.19M | 145.48M | 166.92M |
| Retained Earnings | -2.78B | -2.38B | -2.01B | -1.57B | -1.17B | -830.19M | -570.61M | -372.76M | -249.18M | -157.12M |
| Total Debt | — | 1.00M | 1.00M | 1.00M | 1.00M | — | — | — | — | — |
| Net Cash (Debt) | 296.98M | 322.78M | 278.87M | 470.85M | 503.41M | 629.44M | 307.08M | 468.52M | 145.37M | 166.47M |
| Shares Outstanding | 411.94M | 305.25M | 256.14M | 187.81M | 157.00M | 147.87M | 126.41M | 123.42M | 73.16M | 62.25M |
This table shows 10 annual periods of Iovance Biotherapeutics's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IOVA's reporting calendar. What is a balance sheet?